Effect of antifungal therapy timing on mortality in cancer patients with candidemia

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 184-190

  Taur, Ying ^a   Cohen, Nina ^a   Dubnow, Sarah ^a   Paskovaty, Alla ^a   Seo, Susan K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; APACHE; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD CULTURE; CANCER MORTALITY; CANDIDA; CANDIDEMIA; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; INCUBATION TIME; INFANT; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; APACHE; BLOOD; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; INFANT; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 73849109156     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00945-09     Document Type: Article

References (48)

1. Abi-Said, D., O. Uzun, and E. Anaissie. 1996. Use of severity score indexes for stratification of prognosis in hospitalized cancer patients with candidemia. Abstr. 36th Intersci. Conf. Antimicrob. Agents Chemother., abstr. J43. American Society for Microbiology, Washington, DC.
2. Anaissie, E. J., J. H. Rex, O. Uzun, and S. Vartivarian. 1998. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. 104:238-245.
3. Ben-Ami, R., M. Weinberger, R. Orni-Wasserlauff, D. Schwartz, A. Itzhaki, T. Lazarovitch, E. Bash, Y. Aharoni, I. Moroz, and M. Giladi. 2008. Time to blood culture positivity as a marker for catheter-related candidemia. J. Clin. Microbiol. 46:2222-2226.
4. Bennett, J. 2008. Is real-time polymerase chain reaction ready for real use in detecting candidemia? Clin. Infect. Dis. 46:897-898.
5. Blot, S., K. Vandewoude, E. Hoste, J. Poelaert, and F. Colardyn. 2001. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. J. Hosp. Infect. 47:308-313.
6. Blumberg, H. M., W. R. Jarvis, J. M. Soucie, J. E. Edwards, J. E. Patterson, M. A. Pfaller, M. S. Rangel-Frausto, M. G. Rinaldi, L. Saiman, R. T. Wiblin, and R. P. Wenzel. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33:177-186.
7. Bodey, G. P., M. Mardani, H. A. Hanna, M. Boktour, J. Abbas, E. Girgawy, R. Y. Hachem, D. P. Kontoyiannis, and I. I. Raad. 2002. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112:380-385.
8. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement, CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Cruciani, M., F. de Lalla, and C. Mengoli. 2005. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med. 31:1479-1487.
10. Eggimann, P., P. Francioli, J. Bille, R. Schneider, M. M. Wu, G. Chapuis, R. Chiolero, A. Pannatier, J. Schilling, S. Geroulanos, M. P. Glauser, and T. Calandra. 1999. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care Med. 27:1066-1072.
11. Fraser, V. J., M. Jones, J. Dunkel, S. Storfer, G. Medoff, and W. C. Dunagan. 1992. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15:414-421.
12. Garbino, J., D. P. Lew, J.-A. Romand, S. Hugonnet, R. Auckenthaler, and D. Pittet. 2002. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 28:1708-1717.
13. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
14. Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
15. Holley, A., J. Dulhunty, S. Blot, J. Lipman, S. Lobo, C. Dancer, J. Rello, and G. Dimopoulos. 2009. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int. J. Antimicrob. Agents 33: 554.e1-554.e7.
16. Horvath, L. L., B. J. George, C. K. Murray, L. S. Harrison, and D. R. Hospenthal. 2004. Direct comparison of the BACTEC 9240 and BacT/ ALERT 3D automated blood culture systems for Candida growth detection. J. Clin. Microbiol. 42:115-118.
17. Ilstrup, D. M., and J. A. Washington. 1983. The importance of volume of blood cultured in the detection of bacteremia and fungemia. Diagn. Microbiol. Infect. Dis. 1:107-110.
18. Khatib, R., K. Riederer, S. Saeed, L. B. Johnson, M. G. Fakih, M. Sharma, M. S. Tabriz, and A. Khosrovaneh. 2005. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection. Clin. Infect. Dis. 41:594-598.
19. Knaus, W. A., D. P. Wagner, E. A. Draper, J. E. Zimmerman, M. Bergner, P. G. Bastos, C. A. Sirio, D. J. Murphy, T. Lotring, A. Damiano, et al. 1991. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100:1619-1636.
20. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
21. Labelle, A. J., S. T. Micek, N. Roubinian, and M. H. Kollef. 2008. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 36:2967-2972.
22. León, C., S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, F. Alvarez-Lerma, J. Garnacho-Montero, and M. A. León. 2006. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit. Care Med. 34:730-737.
23. Maaroufi, Y., J. M. De Bruyne, V. Duchateau, A. Georgala, and F. Crokaert. 2004. Early detection and identification of commonly encountered Candida species from simulated blood cultures by using a real-time PCR-based assay. J. Mol. Diagn. 6:108-114.
24. Marra, A. R., M. B. Edmond, B. A. Forbes, R. P. Wenzel, and G. M. Bearman. 2006. Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J. Clin. Microbiol. 44:1342-1346.
25. McMullan, R., L. Metwally, P. V. Coyle, S. Hedderwick, B. McCloskey, H. J. O'Neill, C. C. Patterson, G. Thompson, C. H. Webb, and R. J. Hay. 2008. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin. Infect. Dis. 46:890-896.
26. Moreira-Oliveira, M. S., Y. Mikami, M. Miyaji, T. Imai, A. Z. Schreiber, and M. L. Moretti. 2005. Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:721-726.
27. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
28. Nolla-Salas, J., A. Sitges-Serra, C. Leon-Gil, J. Martinez-Gonzalez, M. A. Leon-Regidor, P. Ibanez-Lucia, and J. M. Torres-Rodriguez. 1997. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 23:23-30.
29. Nucci, M., M. I. Silveira, N. Spector, F. Silveira, E. Velasco, T. Akiti, G. Barreiros, A. Derossi, A. L. Colombo, and W. Pulcheri. 1998. Risk factors for death among cancer patients with fungemia. Clin. Infect. Dis. 27:107-111.
30. Ostrosky-Zeichner, L., B. D. Alexander, D. H. Kett, J. Vazquez, P. G. Pappas, F. Saeki, P. A. Ketchum, J. Wingard, R. Schiff, H. Tamura, M. A. Finkelman, and J. H. Rex. 2005. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41:654-659.
31. Ostrosky-Zeichner, L., C. Sable, J. Sobel, B. D. Alexander, G. Donowitz, V. Kan, C. A. Kauffman, D. Kett, R. A. Larsen, V. Morrison, M. Nucci, P. G. Pappas, M. E. Bradley, S. Major, L. Zimmer, D. Wallace, W. E. Dismukes, and J. H. Rex. 2007. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 26:271-276.
32. Paphitou, N. I., L. Ostrosky-Zeichner, and J. H. Rex. 2005. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med. Mycol. 43:235-243.
33. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, and W. E. Dismukes. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
34. Park, S., M. Wong, S. A. Marras, E. W. Cross, T. E. Kiehn, V. Chaturvedi, S. Tyagi, and D. S. Perlin. 2000. Rapid identification of Candida dubliniensis using a species-specific molecular beacon. J. Clin. Microbiol. 38:2829-2836.
35. Pelz, R. K., C. W. Hendrix, S. M. Swoboda, M. Diener-West, W. G. Merz, J. Hammond, and P. A. Lipsett. 2001. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. 233:542-548.
36. Peralta, G., M. P. Roiz, M. B. Sanchez, J. C. Garrido, B. Ceballos, M. J. Rodriguez-Lera, F. Mateos, and I. De Benito. 2007. Time-to-positivity in patients with Escherichia coli bacteraemia. Clin. Microbiol. Infect. 13:1077-1082.
37. Pittet, D., M. Monod, P. M. Suter, E. Frenk, and R. Auckenthaler. 1994. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg. 220:751-758.
38. Playford, E. G., A. C. Webster, T. C. Sorrell, and J. C. Craig. 2006. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J. Antimicrob. Chemother. 57:628-638.
39. Puzniak, L., S. Teutsch, W. Powderly, and L. Polish. 2004. Has the epidemiology of nosocomial candidemia changed? Infect. Control Hosp. Epidemiol. 25:628-633.
40. Schelonka, R. L., M. K. Chai, B. A. Yoder, D. Hensley, R. M. Brockett, and D. P. Ascher. 1996. Volume of blood required to detect common neonatal pathogens. J. Pediatr. 129:275-278.
41. Sendid, B., T. Jouault, R. Coudriau, D. Camus, F. Odds, M. Tabouret, and D. Poulain. 2004. Increased sensitivity of mannanemia detection tests by joint detection of alpha- and beta-linked oligomannosides during experimental and human systemic candidiasis. J. Clin. Microbiol. 42:164-171.
42. Shorr, A. F., K. Chung, W. L. Jackson, P. E. Waterman, and M. H. Kollef. 2005. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit. Care Med. 33:1928-1936.
43. Uzun, O., and E. J. Anaissie. 2000. Predictors of outcome in cancer patients with candidemia. Ann. Oncol. 11:1517-1521.
44. van Deventer, A. J., W. H. Goessens, A. van Belkum, H. J. van Vliet, E. W. van Etten, and H. A. Verbrugh. 1995. Improved detection of Candida albicans by PCR in blood of neutropenic mice with systemic candidiasis. J. Clin. Microbiol. 33:625-628.
45. Vardakas, K. Z., G. Samonis, A. Michalopoulos, E. S. Soteriades, and M. E. Falagas. 2006. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit. Care Med. 34:1216-1224.
46. Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmery, B. De Pauw, and F. Meunier. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.
47. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.
48. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.